Chemistry:Gumarontinib
From HandWiki
Gumarontinib is a pharmaceutical drug used for the treatment of cancer. In China, it was conditionally approved in 2023 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.[1]
Gumarontinib is a selective MET—hepatocyte growth factor receptor—inhibitor.[2]
References
- ↑ "NMPA conditionally approves gumarontinib for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation". 10 March 2023. https://ecancer.org/en/news/22782-nmpa-conditionally-approves-gumarontinib-for-treatment-of-non-small-cell-lung-cancer-with-met-exon-14-skipping-mutation.
- ↑ "Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial". eClinicalMedicine 59. May 2023. doi:10.1016/j.eclinm.2023.101952. PMID 37096188.
 |  |
